Immuno-Oncology

The AJMC® Immuno-Oncology compendium is a comprehensive resource for clinical news and expert insights for treatments that utilize the body's immune system to fight cancer, such as immune checkpoint inhibitors and chimeric antigen receptor T-cell therapies.

Latest News

Travis Osterman, DO, MS, FAMIA, FASCO
Leveraging AI to Optimize Precision Immunotherapy at Vanderbilt

October 25th 2024

The theme of our recent Nashville Institute for Value-Based Medicine® event was ”Bringing the Future to the Present in Cancer Care.”

Advances in the Treatment of Resectable NSCLC: Key Insights From CheckMate 77T, NEOSTAR, and CA209-159 Trials
Advances in the Treatment of Resectable NSCLC: Key Insights From CheckMate 77T, NEOSTAR, and CA209-159 Trials

September 15th 2024

Rates of ICI-related CVAEs and myocarditis were low, but the risk of mortality following CVAEs is high, underscoring the need for monitoring and management of these effects. | Image credit: Henadzy - stock.adobe.com
Early Recognition, Action Crucial for ICI-Induced Cardiovascular Adverse Effects

August 30th 2024

The Challenge With CAR T? It’s Not the Drug, It’s the Delivery
The Challenge With CAR T? It’s Not the Drug, It’s the Delivery

August 24th 2024

Jeff Patton, MD | Image: OneOncology
OneOncology Announces Deal to Acquire United Urology Group

August 20th 2024

ASCO 2024: Latest Data in Melanoma

Gain expert insights to the phase 3 NADINA trial and learn more about unmet needs in melanoma management with this Post Conference Perspectives.

Gain expert insights to the phase 3 NADINA trial and learn more about unmet needs in melanoma management with this Post Conference Perspectives.

More News

Cost-Effectiveness Analysis
March 18th 2021

Axi-cel May Add Years, Decrease Cost vs Tisa-cel in Large B-Cell Lymphoma

Rose McNulty
A new cost-effectiveness analysis suggests quality-adjusted life year gain and cost reduction for patients treated with axicabtagene ciloleucel versus tisagenlecleucel.
FDA to Reassess 6 Oncology Immunotherapy Indications Granted Accelerated Approval
March 12th 2021

FDA to Reassess 6 Oncology Immunotherapy Indications Granted Accelerated Approval

Rose McNulty Anthony Hagen
The FDA will reassess 6 indications for immune checkpoint inhibitors that were granted accelerated approval but failed to prove clinical benefit in confirmatory trials.
Blood Cells
March 11th 2021

Experimental Safety Switch Has Potential to Reduce CAR T Side Effects

Rose McNulty
An experimental safety switch incorporated into chimeric antigen receptor (CAR) T-cell therapy reduced the severity of the treatment’s side effects in an early-phase trial.
Patient Reporting Symptoms in PRO System
March 5th 2021

Targeted PRO Tools Needed to Evaluate QOL in Immuno-Oncology Trials

Rose McNulty
A review published in Cancer examines the efficacy and drawbacks of tools used to evaluate health-related quality of life in immuno-oncology clinical trials.
DNA
March 5th 2021

Circulating T Cells Provide Insight on Tumor Sister Cells in Advanced Melanoma

Rose McNulty
A new study found that performing single-cell RNA sequencing on T cells circulating in the blood provided significant insight on sister cells within tumor tissue in advanced melanoma.
ASH 2020: CAR T-Cell Therapy Updates
January 20th 2021

ASH 2020: CAR T-Cell Therapy Updates

Mary Caffrey Maggie L. Shaw
Exciting new and ongoing developments in chimeric antigen receptor (CAR) T-cell therapies were covered at the 62nd American Society of Hematology (ASH) annual meeting.
Dr. Chris O'Callaghan
October 30th 2020

Drug That Boosts Immunotherapy Studied as Tool to Battle COVID-19 in Patients With Cancer

Mary Caffrey
An investigational drug, IMM-101, already being studied for its ability to increase the effects of immuno-oncology agents, may be able to prevent or lessen the effects of COVID-19 among those with cancer.
Best Cancer Tests Don't Reach All Who Need Them
August 17th 2020

Best Cancer Tests Don't Reach All Who Need Them

AJMC Staff
Evidence-Based Oncology managed care updates for August 2020 feature coverage of liquid biopsies, companion diagnostics, and CAR T-cell therapy.
Site Logo
May 1st 2019

The Promise of Specialty Oncology Innovations in the Drug Pipeline

Silas Inman
The oncology drug pipeline has experienced rapid growth over the past decade, driven by innovation in cell therapies, immunotherapy, and precision medicine, according to a specialty pipeline update presentation at Asembia's 15th annual Specialty Pharmacy Summit, held April 29 to May 2 in Las Vegas.
Dr Lee Schwartzberg Reflects on the Approval of the First Immunotherapy Regimen in Breast Cancer
April 12th 2019

Dr Lee Schwartzberg Reflects on the Approval of the First Immunotherapy Regimen in Breast Cancer

The breast cancer community is very excited about the approval of atezolimuab for the treatment of triple-negative breast cancer, explained Lee Schwartzberg, MD, FACP, executive director, West Cancer Center.
Site Logo
March 7th 2019

Cost Differential of Immuno-Oncology Therapy Delivered at Community Versus Hospital Clinics

Lucio Gordan, MD Marlo Blazer, PharmD, BCOP Vishal Saundankar, MS Denise Kazzaz Susan Weidner, MS Michael Eaddy, PharmD, PhD
Administration of immuno-oncology therapy for cancer diagnoses in the community clinic setting is associated with lower costs compared with administration in a hospital-based clinic setting.
This Week in Managed Care: February 15, 2019
February 15th 2019

This Week in Managed Care: February 15, 2019

This week, the top managed care news included increased demand for long-acting contraception since President Trump took office; a payer decision on an insulin pump alarmed diabetes advocates; and despite being involved in cancer treatment decisions, many primary care providers don't feel prepared to do so.
Site Logo
February 14th 2019

Finding the Right Combination for Neoadjuvant Therapy in High-Risk, Stage III Melanoma

Mary Caffrey
Evidence-Based OncologyTM recently sat down with Rodabe Amaria, MD, assistant professor in the Department of Melanoma Medical Oncology, Division of Cancer Medicine, at MD Anderson and a lead author on a study that found that evidence has been accumulating in preclinical models that neoadjuvant treatment may be superior to treatment after surgery for patients with advanced melanoma.
Site Logo
February 13th 2019

Is Immunotherapy the Future of Glioblastoma Treatment?

Samantha DiGrande
Immunotherapy has seen great success in the treatment of numerous cancers, from melanoma to lung, breast, colorectal, kidney, and even some brain cancers. But thus far, despite several attempts, the devastating brain disease glioblastoma has not been among the immunotherapy success stories. In fact, glioblastoma researchers have had few advances in more than a decade.
Tumor Mutational Burden Predicts Who Will Respond to Immunotherapy
January 19th 2019

Tumor Mutational Burden Predicts Who Will Respond to Immunotherapy

Jaime Rosenberg
Higher tumor mutational burden is associated with improved overall survival in patients with stage IV or metastatic disease being treated with immune checkpoint inhibitors.
Ted Okon: A Different Reimbursement Approach Is Needed for CAR T, Other Innovative Therapies
December 27th 2018

Ted Okon: A Different Reimbursement Approach Is Needed for CAR T, Other Innovative Therapies

As new, innovative therapies with high price tags, such as chimeric antigen receptor (CAR) T-cell therapy, come to market, the US health system will have to start looking at different approaches for reimbursement, said Ted Okon, MBA, executive director of the Community Oncology Alliance.
Pembrolizumab Superior to Standard of Care in SCC
December 26th 2018

Pembrolizumab Superior to Standard of Care in SCC

Samantha DiGrande
A recent trial looked to compare the efficacy and safety of pembrolizumab (Keytruda) with the standard of care for the treatment of head and neck squamous cell carcinoma (SCC).
FDA Grants Accelerated Approval to Pembrolizumab for MCC
December 22nd 2018

FDA Grants Accelerated Approval to Pembrolizumab for MCC

Samantha DiGrande
Earlier this week, the FDA granted accelerated approval to pembrolizumab (Keytruda) for adult and pediatric patients with recurrent locally advanced or metastatic Merkel cell carcinoma (MCC).
Soluble CD163 Potential Biomarker in Advanced Cutaneous Melanoma
December 21st 2018

Soluble CD163 Potential Biomarker in Advanced Cutaneous Melanoma

David Bai, PharmD
Patients with advanced cutaneous melanoma who are responsive to nivolumab (Opdivo) have higher serum levels of soluble CD163 (sCD163) compared with nonresponders, according to the results of a recent study.
The Allen Institute for Immunology Plans Long-term Goal of Mapping the Immune System
December 15th 2018

The Allen Institute for Immunology Plans Long-term Goal of Mapping the Immune System

David Bai, PharmD
The Allen Institute for Immunology has partnered with several cancer institutions, including the Fred Hutchinson Cancer Research Center, with the primary goal of understanding the differences between a defective and healthy immune system to improve immune-based treatments.
Dr Brian Koffman Explains How PROs Can Provide Insight Into CAR T Benefits
December 12th 2018

Dr Brian Koffman Explains How PROs Can Provide Insight Into CAR T Benefits

While patient-reported outcomes don’t provide the whole story, they can provide insight into how chimeric antigen receptor (CAR) T-cell therapy changes a patient’s life, said Brian Koffman, MDCM, DCFP, DABFM, MS Ed, medical director, CLL Society.
Longer-Term JULIET Results Confirm Sustained Response With Tisagenlecleucel in Relapsed/Refractory DLBCL
December 6th 2018

Longer-Term JULIET Results Confirm Sustained Response With Tisagenlecleucel in Relapsed/Refractory DLBCL

Surabhi Dangi-Garimella, PhD
A median 19-month follow-up of the JULIET trial—a single-arm, open-label, multicenter, global, pivotal phase 2 trial of the chimeric antigen receptor-T cell therapy tisagenlecleucel directed against CD19-expressing B cells—has found a 40% complete response and a manageable safety profile in adult patients with relapsed/refractory (R/R) diffuse large B-cell lymphoma (DLBCL).
Carfilzomib-Based Combination Results in Sustained MRD-Negative Complete Response in Multiple Myeloma
December 6th 2018

Carfilzomib-Based Combination Results in Sustained MRD-Negative Complete Response in Multiple Myeloma

Jaime Rosenberg
Researchers at the 60th American Society of Hematology Annual Meeting & Exposition presented long-term study results showing that high rates of minimal residual disease–negative complete response were sustained with a median duration of over 4 years among treatment-naïve patients with multiple myeloma.
Site Logo
December 4th 2018

The Value of Novel Immuno-Oncology Treatments

John A. Romley, PhD Andrew Delgado, PharmD Jinjoo Shim, MS Katharine Batt, MD
This study assesses the value of novel immuno-oncology treatments to society.
Dr Michael Kolodziej Discusses Concerns Around Paying for Innovative Treatments, Like CAR T
December 3rd 2018

Dr Michael Kolodziej Discusses Concerns Around Paying for Innovative Treatments, Like CAR T

While new therapies like chimeric antigen receptor (CAR) T-cell therapy, can have amazing results, the innovation of these treatments has outstripped the United States’ ability to pay for them, said Michael Kolodziej, MD, vice president and chief innovation officer at ADVI Health, Inc.
Site Logo
December 2nd 2018

Real-World Evidence With Axicabtagene Ciloleucel CAR T Treatment Similar to ZUMA-1 Trial Findings

Surabhi Dangi-Garimella, PhD
A multicenter retrospective study that evaluated the efficacy and safety of chimeric antigen receptor (CAR) T-cell treatment, axicabtagene ciloleucel (axi-cel; Yescarta), in a real-world setting found a similar response as well as toxicity compared with the ZUMA-1 clinical trial.
Larotrectinib Approved to Treat Patients With Advanced Solid Tumors Expressing NTRK
November 30th 2018

Larotrectinib Approved to Treat Patients With Advanced Solid Tumors Expressing NTRK

Samantha DiGrande
This week, the FDA approved larotrectinib, to be sold as Vitrakvi, for the treatment of adult and pediatric patients with solid tumors that have a neurotrophic receptor tyrosine kinase (NTRK) gene infusion without a known acquired resistance mutation, are metastatic or where surgical resection is likely to result in severe morbidity, and have no satisfactory alternative treatments or that have progressed following treatment.
CD7 CAR T Cells Selectively Target Leukemic Cells in Patients With AML
November 25th 2018

CD7 CAR T Cells Selectively Target Leukemic Cells in Patients With AML

David Bai, PharmD
CD7 gene-edited chimeric antigen receptor (CAR) T cells target CD7-positive acute myeloid leukemia (AML) cells while sparing myeloid and erythroid cells and minimizing toxicity, according to the results of a recent study.
Dr Brian Koffman Outlines the Follow-up as a Patient Treated With CAR T
November 24th 2018

Dr Brian Koffman Outlines the Follow-up as a Patient Treated With CAR T

After being treated for his chronic lymphocytic leukemia with chimeric antigen receptor (CAR) T-cell therapy, Brian Koffman, MDCM, DCFP, DABFM, MS Ed, medical director, CLL Society, is being followed for 15 years to better understand if there are any undiscovered adverse events that pop up and how durable the response is.
FDA Approves Pembrolizumab to Treat HCC
November 20th 2018

FDA Approves Pembrolizumab to Treat HCC

Samantha DiGrande
Earlier this month, Merck announced that the FDA approved its anti–PD-1 therapy, pembrolizumab (sold as Keytruda), for the treatment of patients with hepatocellular carcinoma (HCC) who have been previously treated with sorafenib.
<1
...
5678910111213
...
15>

2 Commerce Drive
Suite 100
Cranbury, NJ 08512

© 2024 MJH Life Sciences® and AJMC®.
All rights reserved.

About
Contact
Editorial Boards
Advertise
Do Not Sell My Information
Terms & Conditions
Privacy Policy
AJMC Managed Markets Network Logo
CH LogoCenter for Biosimilars Logo